



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Paola Gazzaniga**
 Address(es) Department of Molecular Medicine, Viale Regina Elena 324, 00161, Rome, Italy
 Fax(es)
 E-mail paola.gazzaniga@uniroma1.it
 Nationality italian

Occupational field Molecular oncology

Work experience

Dates 2001 to date
 Occupation or position held Assistant professor
 Main activities and responsibilities Liquid biopsies in patients with solid tumors
 Name and address of employer Sapienza University of Rome
 Sector Translational oncology

Education and training

Dates 1999
 Title of qualification awarded Residency in Medical Oncology
 Name and type of organisation providing education and training Sapienza^o University, Roma, Italy

Dates 1995
 Title of qualification awarded Ph.D
 Name and type of organisation providing education and training University of l'Aquila

Dates 1991
 Title of qualification awarded MD
 Name and type of organisation providing education and training Sapienza^o University, Roma, Italy

Personal skills and competences Good experience in project and team management.

Mother tongue(s) **Italian**

Other language(s) **english**

Self-assessment
 European level (*)

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	

English Language	C1	C1	C1	C1	C1

(*) [Common European Framework of Reference for Languages](#)

PUBLICATIONS

- Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, Mastromartino M, Del Bene G, Prete A, Longo F, Cortesi E, Gazzaniga P. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. *Sci Rep*. 2016 Aug 24;6:31726. doi: 10.1038/srep31726
- Nicolazzo C, Massimi I, Lotti LV, Vespa S, Raimondi C, Pulcinelli FM, Gradilone A, Gazzaniga P. Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells. *Chin J Cancer Res*. 2015 Oct;27(5):491-6.
- Gazzaniga P, Raimondi C, Nicolazzo C, Carletti R, di Gioia C, Gradilone A, Cortesi E. The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells. *Expert Rev Mol Diagn*. 2015;15(7):925-32
- Raimondi C, Nicolazzo C, Gradilone A, Giannini G, De Falco E, Chimenti I, Varriale E, Hauch S, Plappert L, Cortesi E, Gazzaniga P. Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer. *Cancer Biol Ther*;15(5):496-503, 2014.
- Gazzaniga P, de Berardinis E, Raimondi C, Gradilone A, Busetto GM, De Falco E, Nicolazzo C, Giovannone R, Gentile V, Cortesi E, Pantel K. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. *Int J Cancer*. Oct 15;135(8):1978-82, 2014.
- Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. *Lancet Oncol*. Apr;15(4):406-14, 2014.
- Raimondi C, Gradilone A, Gazzaniga P. Circulating tumor cells in early bladder cancer: insight into micrometastatic disease. *Expert Rev Mol Diagn*. May;14(4):407-9, 2014 (invited review).
- Raimondi C, Gradilone A, Naso G, Cortesi E, Gazzaniga P. Clinical utility of circulating tumor cell counting through CellSearch®: the dilemma of a concept suspended in Limbo. *Onco Targets Ther*. Apr 17;7:619-625, 2014 (invited review)
- Raimondi C, Gradilone A, Gazzaniga P. Controversies in circulating tumor cell count during therapy. *Expert Rev Mol Diagn*. Jun;13(5):499-507, 2013 (invited review)
- Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, Longo F, Tomao S, Lo Russo G, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati L, Cortesi E. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? *J Cancer Res Clin Oncol*. 139(8):1411-6, 2013.
- Gazzaniga P, Gianni W, Raimondi C, Gradilone A, Lo Russo G, Longo F, Gandini O, Tomao S, Frati L. Circulating tumor cells in high-risk nonmetastatic colorectal cancer. *Tumour Biol*. 34(5):2507-9, 2013
- Gradilone A, Gazzaniga P, Ribuffo D, Bottoni U, Frati L, Agliano AM, Sorvillo V, Piperno A, Scuderi N, Cigna E. Prognostic significance of tyrosinase expression in sentinel lymph node biopsy for ultra-thin, thin, and thick melanomas. *Eur Rev Med Pharmacol Sci*. 16(10):1367-76, 2012
- Cigna E, Gradilone A, Ribuffo D, Gazzaniga P, Fino P, Sorvillo V, Scuderi N. Morbidity of selective lymph node biopsy for melanoma: meta-analysis of complications. *Tumori*. Jan-Feb;98(1):94-8, 2012
- Gazzaniga P, Gianni W, Gradilone A, Raimondi C, Cortesi E, Frati L. Circulating Tumor Cells In Young And Elderly Patients With Colorectal Cancer: "Lupus Et Agnus" *Aging Clin Exp Res*. 24(6):722-3, 2012.
- Gazzaniga P, Gradilone A, de Berardinis E, Busetto GM, Raimondi C, Gandini O, Nicolazzo C, Petracca A, Vincenzi B, Farcomeni A, Gentile V, Cortesi E, Frati L. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. *Ann Oncol*. 23(9):2352-6, 2012.
- Gazzaniga P, Raimondi C, Gradilone A, Naso G, Cortesi E, Frati L. Circulating tumor cells: highlight on practical implications. *Mol Diagn Ther*. Feb 1;16(1):7-11, 2012
- Gradilone A, Iacovelli R, Cortesi E, Raimondi C, Gianni W, Nicolazzo C, Petracca A, Palazzo A, Longo F, Frati L, Gazzaniga P. Circulating tumor cells and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma. *Anticancer Res*. Dec;31(12):4219-21, 2011.
- Gradilone A, Raimondi C, Naso G, Silvestri I, Repetto L, Palazzo A, Gianni W, Frati L, Cortesi E, Gazzaniga P. How circulating tumor cells escape from multidrug resistance: translating molecular mechanisms in metastatic breast cancer treatment. *Am J Clin Oncol*. Dec;34(6):625-7, 2011
- Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, Gazzaniga P. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. *Breast Cancer Res Treat*. Nov;130(2):449-55, 2011
- Iacovelli R, Palazzo A, Procopio G, Gazzaniga P, Cortesi E. Abiraterone acetate in castration-resistant prostate cancer. *Anticancer Drugs*. Mar;23(3):247-54, 2011

21. Gazzaniga P, Naso G, Raimondi C, Gradilone A, Palazzo A, Gandini O, Petracca A, Nicolazzo C, Cortesi E, Frati L. Circulating tumor cells count and characterization in a male breast cancer patient. *Cancer Biol Ther.* Sep 1;12(5):379-82, 2011
22. Gazzaniga P, Raimondi C, Gradilone A, Di Seri M, Longo F, Cortesi E, Frati L. Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero. *Ann Oncol.* Aug;22(8):1929-30, 2011
23. Mattiello T, Guerriero R, Lotti LV, Trifirò E, Felli MP, Barbarulo A, Pucci B, Gazzaniga P, Gaudio C, Frati L, Pulcinelli FM. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. *J Am Coll Cardiol.* Aug 9;58(7):752-61, 2011. Erratum in: *J Am Coll Cardiol.* Oct 18;58(17):1832, 2011
24. A. Gradilone, G. Naso., C. Raimondi, E. Cortesi, O. Gandini, B. Vincenzi, R. Saltarelli, E. Chiapparino, F. Spremberg, M. Cristofanilli, L. Frati, A.M. Aglianò, and P. Gazzaniga. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): Prognosis, drug resistance and phenotypic characterization. *Annals Oncol.* Jan;22(1):86-92, 2011
25. Gradilone A, Gazzaniga P, Raimondi C, Aglianò AM, Frati L. Comment on: isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. *Int J Cancer.* Apr 15;128(8):1997-8, 2011
26. Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, Naso G, Aglianò AM, Cortesi E, Gazzaniga P. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. *J Cell Mol Med.* May;15(5):1066-70, 2011
27. Gazzaniga P, Cigna E, Panasiti V, Devirgiliis V, Bottoni U, Vincenzi B, Nicolazzo C, Petracca A, Gradilone A. CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients. *Eur J Surg Oncol.* Dec;36(12):1211-4, 2010
28. P. Gazzaniga, A. Gradilone, A. Petracca, C. Nicolazzo, C. Raimondi, R. Iacovelli, G. Naso, E. Cortesi. Molecular markers in circulating tumor cells from metastatic colorectal cancer patients *J Cell Mol Med.* Aug;14(8):2073-7, 2010
29. Raimondi C, Naso G, Gradilone A, Gianni W, Cortesi E, Gazzaniga P. Circulating Tumor Cells in Cancer Therapy: Are we Off Target? *Curr Cancer Drug Targets.* Aug;10(5):509-18, 2010 (invited review)
30. Raimondi C, Cortesi E, Gianni W, Gazzaniga P. Cancer Stem Cells and Epithelial-Mesenchymal Transition: Revisiting Minimal Residual Disease. *Curr Cancer Drug Targets.* Aug;10(5):496-508, 2010 (invited review).
31. Gazzaniga P. Cancer Therapy: Are we Missing the Target? *Curr Cancer Drug Targets.* Aug;10(5):432, 2010 (invited review).
32. Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, Naso G, Vincenzi B, Cristini C, de Berardinis E, di Silverio F, Aglianò AM, Gazzaniga P. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. *BJU Int.* 106(5):710-5, 2010
33. Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, Fabbri MA, Vincenzi B, di Silverio F, Frati L, Aglianò AM, Cristofanilli M. Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. *Int J Cancer.* May 15;126(10):2437-47, 2010
34. Paola Gazzaniga, Angela Gradilone, Ettore de Berardinis, Alessandro Sciarra, Cristiano Cristini, Giuseppe Naso, Franco di Silverio, Luigi Frati, Anna Maria Aglianò. A chemosensitivity test to individualize intravesical treatment in non muscle invasive bladder cancer. *BJU Int.* 104(2):184-8, 2009
35. Gianni W., Gazzaniga P., Zuccaro S., Giuseppe Luzi Don't worry, Your Holiness! *BMJ*;338:b39, doi: 10.1136/bmj.b39, 2009
36. Gazzaniga P, Cigna E, Vincenzi B, Bottoni U, Vasaturo F, Alfano C, Calvieri S, Frati L, Scuderi N, Aglianò AM, Gradilone A. Tenascin C: A defensive role in sentinel lymph nodes of melanoma patients? *J Dermatol Sci.* Mar;53(3):239-41, 2008
37. A. Gradilone, A. Spadaro, W. Gianni, A. M. Aglianò, and P. Gazzaniga. Induction of multidrug resistance proteins in lymphocytes from patients with arthritic disorders. *Clinical and Experimental Medicine.* Dec;8(4):229-30, 2008
38. A. Gradilone, F. M. Pulcinelli, L. V. Lotti, E. Trifirò, S. Martino, O. Gandini, W. Gianni, L. Frati, A. M. Aglianò, and P. Gazzaniga. Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. *Current Cancer Drugs Targets,* Aug;8(5):414-20, 2008
39. Gazzaniga P., Gradilone A., Naso G., Cortesi E., Gianni W., Frati L., Aglianò A. M. Chemoresistance profile of circulating tumor cells: toward a clinical benefit? *Int. J. Cancer,* Oct 1;123(7):1730-2, 2008
40. Gazzaniga P., Silvestri I., Gradilone A., Aglianò A.M. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. *BJU Int.* Jan;101(1):127, 2008
41. Gradilone A., Pulcinelli F.M.i, Lotti L.V., Martino S., Mattiello T., Frati L., Aglianò A.M., Gazzaniga P. Celecoxib induces MRP 4 in lung cancer cells: therapeutic implications. *J. Clin. Oncol.* Sep 20;25(27):4318-20, 2007
42. Stigliano A., Gandini O., Cerquetti L., Gazzaniga P., Misiti S., Monti S., Gradilone A., Falasca P., Poggi M., Brunetti E., Aglianò A. M. and Toscano V. Increased MLN64 and CYP17 expression are associated with high staged prostate cancer. *J. Endocr.* Jul;194(1):55-61, 2007
43. A. Gradilone, P. Gazzaniga, E. Cigna, F. Vasaturo, B. Vincenzi, O. Gandini, I. Silvestri, D. Ribuffo, S. Scarpa, N. Scuderi, AM Aglianò. Fibronectin and laminin expression in sentinel lymph nodes of melanoma patients. *Br. J. Dermatol.* Aug;157(2):398-401, 2007
44. Gradilone A., Silvestri I., Scarpa S., Morrone S., Gandini O., Pulcinelli F. M., Gianni W., Aglianò A.M., Gazzaniga P. Failure of apoptosis and activation of NFκB by celecoxib and aspirin in lung cancer cell lines. *Oncol. Rep.* Apr;17(4):823-8, 2007
45. Gazzaniga P., Silvestri I., Gradilone A., Scarpa S., Morrone S., Gandini O., Gianni W., Frati L., Aglianò A. M. Gemcitabine induced apoptosis in 5637 cell line: an in vitro model for superficial bladder cancer. *Anticancer Drugs.* Feb;18(2):179-85, 2007
46. Gazzaniga P., Nofroni I., Gandini O., Silvestri I., Frati L., Aglianò A. M., Gradilone A. Tenascin c and epidermal growth factor receptor as markers of circulating tumor cells in bladder and colon cancer. *Oncol Rep.* Nov;14(5):1199-202, 2005
47. Repetto L., Gianni W., Aglianò A.M. and Gazzaniga P. Impact of EGFR expression on colorectal cancer patients prognosis and survival: a response. *Ann. Oncol.* Sep;16(9):1557, 2005
48. Gradilone A., Ribuffo D., Silvestri I., Cigna E., Gazzaniga P., Nofroni I., Zamolo G., Frati L., Scuderi N., Aglianò A.M. Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase polymerase chain reaction: prognostic significance. *Annals of Surg. Oncol.*, Nov. 11 (11) . 983-7, 2004
49. Gianni W., Ricci A., Gazzaniga P., Brama M., Pietropaolo M., Votano S., Patanè F., Aglianò A. M, Spera G., Marigliano V., Ammendola S., Agnusdei D., Migliaccio S. and Scandurra R. Raloxifene modulates IL-6 and TNF alpha synthesis in vivo: results from a pilot clinical study. *J. Clin Endocrinol. and Metab.* Dec, 89 (12): 6097-9, 2004
50. Messina E., Gazzaniga P., Micheli V., Barile L., Lupi F., Aglianò A. M., Giacomello A. Low levels of mycophenolic acid induce differentiation of human neuroblastoma cell lines. *Int. J. Cancer,* Nov 1; 112 (2): 352-354, 2004

51. Gradilone A., Gazzaniga P., Ribuffo D., Scarpa S., Cigna E., Vasaturo F., Bottoni U., Innocenzi D., Calvieri S., Scuderi N., Frati L., Agliano A. M. In reply. *J. Clin Oncol.* 22 (13) 2752, 2004
52. E. Messina, P. Gazzaniga, V. Micheli, M. G. Guaglianone, S. Barbato, S. Morrone, L. Frati, A. M. Agliano, A. Giacomello. Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. *Int. J. Cancer*, Mar 1; 108(6): 812-7, 2004
53. L. Giacomelli, W. Gianni, C. Belfiore, O. Gandini, L. Repetto, A. Filippini, L. Frati, A.M. Agliano and P. Gazzaniga. Persistence of EGFR and IL-10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. *Clin Cancer Res*, 2678-2682, 2003
54. Gradilone A., Gazzaniga P., Ribuffo D., Scarpa S., Cigna E., Vasaturo F., Bottoni U., Innocenzi D., Calvieri S., Scuderi A., Frati L., Agliano A. M. Survivin, bcl-2, bax and bcl-x gene expression in lymph node metastases from melanoma patients evaluated by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR). *J Clin Oncol*, Jan 15;21(2):306-12, 2003
55. Gazzaniga P., Gradilone A., Giuliani L., Gandini O., Silvestri I., Nofroni I., Saccani G., Frati L., Agliano A. M. Expression and prognostic significance of livin, survivin and other apoptosis related genes in the progression of superficial bladder cancer. *Annals Oncol.*, 2003 Jan;14(1):85-90
56. A. Gradilone, P. Gazzaniga, I. Silvestri, O. Gandini, L. Trasatti, S. Lauro, L. Frati, AM Agliano. Detection of CK-19, CK-20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. *Oncol. Rep.*, 10 (1): 217-222, 2003
57. Gazzaniga P., Gradilone A., Frati L. and Agliano A.M. Epidermal growth factor receptor (EGFR) mRNA expression in peripheral blood of bladder cancer patients: a potential marker to detect treatment failure. *Clin Cancer Res*, 7(12):4288-9, 2001
58. Magnanti M., Gandini O., Giuliani L., Gazzaniga P., Marti H. H., Gradilone A., Frati L., Agliano A. M., and Gassmann M. Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. *Blood* 98(9): 2872-4, 2001
59. Girasole M., Cricenti A., Generosi R., Silvestri I., Gazzaniga P., Pozzi D., Agliano A.M. Atomic force microscopy detect transient frictional contrasts in apoptotic cells induced by deprivation of interleukin-3. *Appl. Phys. Letters*, 78 (8) 1143-1145, 2001
60. Gazzaniga P., Gandini O., Giuliani L., Magnanti M., Gradilone A., Silvestri I., Gianni W., Gallucci M., Frati L. and Agliano A. M. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. *Clin. Cancer Res.*, 7; 577-583, 2001
61. Magnanti M., Giuliani L., Gandini O., Gazzaniga P., Santemma V., Ciotti M., Saccani G., Frati L., Agliano A. M. Follicle-stimulating hormone, testosterone, and hypoxia differentially regulate UDP-glucuronosyl-transferase 1 isoforms expression in rat Sertoli and peritubular myoid cells. *J. Steroid Biochem Mol Biol*, 74, 3-4, 2000
62. Agliano A. M., Castiglia R., Santangelo C., Silvestri I., Gazzaniga P., Giuliani L., Naso G., Frati L. On chromosomal instability: what is the karyotype of your 32D cell line? *Blood*, June 1, 95 (11): 3636-7, 2000
63. Gandini O., Celi F. S., Magnanti M., Gazzaniga P., Silvestri I., Conti B., Giuliani L., Mentuccia D., Agliano A. M.. Rapid, simple inexpensive step facilitates RNA extraction from whole blood cells. *Lab. Investigation* Dec. 79 (12): 1731-1732, 1999
64. Gazzaniga P., Gandini O., Gradilone A., Silvestri I., Giuliani L., Magnanti M., Gallucci M., Saccani G., Frati L., Agliano A. M. Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses. *Int. J. Oncology*, June 14(6) 1123-1127, 1999
65. Gazzaniga P. and A. M. Agliano. In reply. *Cancer Letters* 1999 Apr. 1; 137 (2): 227-229
66. Gazzaniga P., Vercillo R., Gradilone A., Silvestri I., Gandini O., Napolitano M., Giuliani L., Fioravanti A., Gallucci M., Agliano A. M. Prevalence of Papillomavirus, Epstein-Barr virus, Cytomegalovirus and Herpes Simplex virus type 2 in urinary bladder cancer. *J. Med. Virol.*, Aug. 55(4): 262-267, 1998
67. Gazzaniga P., Gradilone A., Silvestri I., Gandini O., Giuliani L., Vincenzoni A., Gallucci M., Frati L., Agliano A.M. Variable levels of bcl-2, bcl-X and bax mRNA in bladder cancer progression. *Oncology Reports*, Jul 5(4): 901-904, 1998
68. Gazzaniga P., Gradilone A., Silvestri I., Gandini O., Napolitano M., Vercillo R., Vincenzoni A., Gallucci M., Frati L., Agliano A.M. High levels of TGF-alpha mRNA may predict local relapses in low stage urinary bladder cancer. *Eur. J. Cancer*, Vol 34, 6: 934-936, 1998
69. Agliano A.M., Naso G., Silvestri I., Gradilone A., Vercillo R., Napolitano M., Gazzaniga P., Gandini O., Realacci M., Santangelo C., Saccani G., Manzari V. and Frati L. Involvement of bcl-2 and bax gene expression in apoptosis and differentiation of the non-tumorigenic murine hematopoietic cell line, 32DC13(G). *Int. J. Oncology* 11, 1271-1277, 1997
70. Gianni W., De Vincentis G., Ierardi M., Fimognari F.L., Banci M., Gazzaniga P., Cacciafesta M., Di Tondo U., Scopinaro F., Marigliano V. Scintigraphic imaging of hepatic epithelioid hemangioendothelioma. *Digestion* 58: 498-500, 1997
71. Gianni W., Vetta F., Lato P. F. A., Bucher L., Gazzaniga P., Bressan A. M., Birarelli P., Ronzoni S., Cacciafesta M., Piccoli M., Marigliano V. Low NK activity: an unfavorable prognostic marker in elderly patients with cancer. *J Tum Marker Oncology*, 11(2): 161-163, 1996
72. Gradilone A., Vercillo R., Napolitano M., Cardinali G., Gazzaniga P., Silvestri I., Gandini O., Tomao S. and Agliano A.M. Prevalence of human Papillomavirus, Cytomegalovirus and Epstein-Barr virus in the cervix of healthy women. *J. Med. Virol.* Sep 50: 1-4, 1996
73. Gazzaniga P., Gradilone A., Vercillo R., Gandini O., Silvestri I., Napolitano M., Albonici L., Vincenzoni A., Gallucci M., Frati L. Agliano A. M. bcl 2/bax mRNA expression ratio as prognostic factor in low grade urinary bladder cancer. *Int. J. Cancer* Apr. 22 69(2):100-104, 1996
74. Gradilone A., Greco C., Gazzaniga P., Vercillo R., Napolitano M., Gandini O., Mattei F., Frati L., Agliano A. M. Bax gene expression in melanoma metastases. *Journal of Investigative Dermatology* 106, 382, 1996
75. Gazzaniga P., Gallucci, Gradilone A., Gandini O., Vincenzoni A., Gianni W., Naso G., Frati L., Agliano A. M. Detection of bcl-2 RNA in low grade tumours of the urinary bladder. *Eur. J. Cancer* 31A, 12, 2219-2120, 1995
76. Agliano A. M., Gradilone A., Gazzaniga P., Napolitano M., Vercillo R., Albonici L., Naso G., Manzari V., Frati L., Vecchione A. High frequency of human papillomavirus detection in urinary bladder cancer. *Urol. Int.* 53, 125-129, 1994
77. Agliano A. M., Gazzaniga P., Cervigni M., Gradilone A., Napolitano M., Pastore L. I., Manzari V., Frati L., Vecchione A. Detection of human papillomavirus type 16 DNA sequences in paraffin-embedded tissues from the female urinary tract. *Urol. Int.* 52, 208-212, 1994

Roma, 20/03/2017

Signed

Paola Gazzaniga

